CL2016000042A1 - Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. - Google Patents

Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.

Info

Publication number
CL2016000042A1
CL2016000042A1 CL2016000042A CL2016000042A CL2016000042A1 CL 2016000042 A1 CL2016000042 A1 CL 2016000042A1 CL 2016000042 A CL2016000042 A CL 2016000042A CL 2016000042 A CL2016000042 A CL 2016000042A CL 2016000042 A1 CL2016000042 A1 CL 2016000042A1
Authority
CL
Chile
Prior art keywords
inhibitor
combination
treatment
hyperproliferative diseases
erk
Prior art date
Application number
CL2016000042A
Other languages
English (en)
Inventor
Marcia Belvin
John Moffat
Mark Merchant
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2016000042A1 publication Critical patent/CL2016000042A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

METODO PARA EL TRATAMIENTO DE UN TRASTORNO HIPERPROLIFERATIVO QUE COMPRENDE ADMINISTRAR UNA COMBINACIÓN DE UN INHIBIDOR DE MEK Y UN INHIBIDOR DE ERK; SU USO; Y KIT QUE COMPRENDE A LA COMBINACION.
CL2016000042A 2013-09-05 2016-01-08 Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. CL2016000042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361874206P 2013-09-05 2013-09-05

Publications (1)

Publication Number Publication Date
CL2016000042A1 true CL2016000042A1 (es) 2016-08-05

Family

ID=51492945

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000042A CL2016000042A1 (es) 2013-09-05 2016-01-08 Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.

Country Status (21)

Country Link
US (1) US9532987B2 (es)
EP (1) EP3041471A1 (es)
JP (2) JP2016531139A (es)
KR (1) KR20160048807A (es)
CN (1) CN105517548B (es)
AR (1) AR097556A1 (es)
AU (1) AU2014317119B2 (es)
CA (1) CA2916619A1 (es)
CL (1) CL2016000042A1 (es)
EA (1) EA034872B1 (es)
HK (1) HK1218072A1 (es)
IL (1) IL243251B (es)
MA (1) MA38827A1 (es)
MX (1) MX370417B (es)
PE (1) PE20160529A1 (es)
PH (1) PH12016500270A1 (es)
SG (1) SG11201600989VA (es)
TW (1) TW201605477A (es)
UA (1) UA120423C2 (es)
WO (1) WO2015032840A1 (es)
ZA (1) ZA201600091B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2820009T3 (en) * 2012-03-01 2018-04-16 Array Biopharma Inc Serine / threonine kinase inhibitors
CN106029672B (zh) 2013-12-06 2019-03-29 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
JP6642942B2 (ja) * 2013-12-30 2020-02-12 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
WO2016162325A1 (en) 2015-04-07 2016-10-13 Astrazeneca Ab Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors
WO2017080980A1 (en) 2015-11-09 2017-05-18 Astrazeneca Ab Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
LT3374359T (lt) 2015-11-09 2020-03-25 Astrazeneca Ab Dihidroimidazopirazinono deriniai, tinkami panaudoti vėžio gydymui
CN105330643B (zh) 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
AU2017316618A1 (en) 2016-08-23 2019-02-07 Genentech, Inc. Combination therapy for the treatment of pancreatic cancer
DK3425390T3 (da) * 2016-11-25 2021-02-15 Genuv Inc Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf
JP2019019094A (ja) * 2017-07-19 2019-02-07 学校法人福岡大学 変異ｋｒａｓ関連シグナル阻害用組成物
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
EP3684364A4 (en) 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
US11395823B2 (en) 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
US12377063B2 (en) * 2019-07-11 2025-08-05 Emory University Combination therapies for managing cancer
KR102695469B1 (ko) * 2021-07-23 2024-08-14 차의과학대학교 산학협력단 2,4-디아미노피리미딘을 포함하는 암의 예방 또는 치료용 조성물
CN118001281B (zh) * 2023-12-11 2025-10-17 中国科学院深圳先进技术研究院 一种治疗或预防甲基苯丙胺成瘾的药物及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
AU2007286808B2 (en) 2006-08-21 2012-12-06 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
PE20081354A1 (es) 2006-11-30 2008-11-14 Genentech Inc Compuestos de azaindolilo como inhibidores de mek
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
JP5580735B2 (ja) 2007-06-12 2014-08-27 ジェネンテック， インコーポレイテッド Ｎ−置換アザインドール類及び使用方法
US8293763B2 (en) 2007-12-19 2012-10-23 Genentech, Inc. 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
JP5421925B2 (ja) * 2007-12-19 2014-02-19 ジェネンテック， インコーポレイテッド ５−アニリノイミダゾピリジン及び使用の方法
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
ES2426096T3 (es) 2008-07-01 2013-10-21 Genentech, Inc. Derivados de isoindolona como inhibidores de la quinasa MEK y métodos de utilización
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
US20120214828A1 (en) 2009-08-24 2012-08-23 Georgia Hatzivassiliou Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
CA2776944A1 (en) 2009-10-12 2011-05-12 F. Hoffmann-La Roche Ag Combinations of a pi3k inhibitor and a mek inhibitor
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
EP2681215B1 (en) 2011-02-28 2015-04-22 Array Biopharma, Inc. Serine/threonine kinase inhibitors
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US9187462B2 (en) 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
DK2820009T3 (en) 2012-03-01 2018-04-16 Array Biopharma Inc Serine / threonine kinase inhibitors
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2014014308A (es) 2012-05-30 2015-02-12 Hoffmann La Roche Pirrolidino heterociclos.
KR20190057421A (ko) 2012-08-17 2019-05-28 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
TW201408658A (zh) 2012-08-27 2014-03-01 Array Biopharma Inc 絲胺酸／酥胺酸激酶抑制劑
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
MX2015004615A (es) 2012-10-16 2015-07-17 Hoffmann La Roche Inhibidores de serina/treonina cinasa.
CN106029672B (zh) 2013-12-06 2019-03-29 基因泰克公司 丝氨酸/苏氨酸激酶抑制剂
JP6642942B2 (ja) 2013-12-30 2020-02-12 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
BR112016015235A2 (pt) 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
EP3129025B1 (en) 2014-04-09 2019-05-15 Genentech, Inc. Process for the manufacturing of medicaments

Also Published As

Publication number Publication date
AU2014317119A1 (en) 2016-03-03
KR20160048807A (ko) 2016-05-04
PH12016500270A1 (en) 2016-05-16
SG11201600989VA (en) 2016-03-30
EA201690513A1 (ru) 2016-07-29
JP2016531139A (ja) 2016-10-06
ZA201600091B (en) 2017-04-26
EP3041471A1 (en) 2016-07-13
MX370417B (es) 2019-12-10
US9532987B2 (en) 2017-01-03
EA034872B1 (ru) 2020-03-31
CN105517548A (zh) 2016-04-20
WO2015032840A1 (en) 2015-03-12
CN105517548B (zh) 2020-01-21
IL243251B (en) 2019-02-28
TW201605477A (zh) 2016-02-16
MX2016002857A (es) 2016-06-22
US20150111869A1 (en) 2015-04-23
JP2019031517A (ja) 2019-02-28
CA2916619A1 (en) 2015-03-12
AR097556A1 (es) 2016-03-23
AU2014317119B2 (en) 2019-12-05
UA120423C2 (uk) 2019-12-10
PE20160529A1 (es) 2016-05-21
HK1218072A1 (zh) 2017-02-03
MA38827A1 (fr) 2017-10-31

Similar Documents

Publication Publication Date Title
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2016001586A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CL2016000925A1 (es) Inhibidores de bromodominio
PL2976106T3 (pl) Terapia kombinowana obejmująca inhibitor B-Raf i drugi inhibitor
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CR20150462A (es) Inhibidores de erk y sus usos
MX2017001512A (es) Compuestos activos hacia bromodominios.
BR112017008274A2 (pt) dispositivo de transmissão com compensação de deficiência e métodos para o uso com o mesmo
MX2017003933A (es) Metodos de tratamiento de la enfermedad hepatica.
PT3218005T (pt) Compostos que interagem com glicano e métodos de uso
CR20170219A (es) Inhibidores del bromodominio
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
PL3215195T3 (pl) Obudowa i metoda dekontaminacyjna
BR112013027716A2 (pt) gavetas rápidas com rolos e rampa
BR112015030351A2 (pt) método e aparelho para realização de transações locais
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2016001098A1 (es) Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales
TWD171584S (zh) 自動出入閘門
SG10201405683YA (en) Emission Source And Method Of Forming The Same